OUR MISSION IS TO DRAMATICALLY IMPROVE THE LIVES OF PATIENTS BY DEVELOPING BREAKTHROUGH NON-OPIOID PAIN THERAPEUTICS THAT ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS.
Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.
Founded in 2014 and based in San Francisco, California, Concentric is developing a portfolio of non-opioid therapeutics that provide long-lasting pain relief after a single local administration. Our innovative water-soluble prodrugs convert into capsaicin, a potent TRPV-1 agonist, which selectively and reversibly desensitizes pain conducting C-fiber nociceptors. Our therapeutic approach has the potential to be a game changer clinically, while also possessing an unusual, asymmetric risk profile: combining low development path risk in known models with a high potential investor ROI.
We have active development programs for three important and underserved indications: management of post-surgical pain, chronic osteoarthritis pain, and intractable cancer pain. We are currently conducting a Phase 1b clinical study for our flagship post-surgical program, CA-008, and the Company expects to initiate IND-enabling studies in its other two programs during 2018.
The lead molecule for each Concentric program is a TRPV-1 agonist prodrug, designed to be a injected into the local site of pain and by specifically targeting and defunctionalizing C-fibers, provide rapid and long-acting, pain selective, site specific, non-opioid pain relief.
Based on its intrinsic chemical characteristics and unique release profile, Concentric’s portfolio of prodrugs hold the promise of meaningfully decreasing the use of opioids, as well as indirectly decreasing their misuse and abuse. This challenge has gained a high level of national awareness and been deemed a health crisis with multiple governmental agencies including NIH, FDA and CDC actively seeking effective non-opioid therapies for pain.